Ayurvedic management of kampavata (Parkinson's disease) - A case study report

Sahoo, Srinibash; Doddamani, Shashidhar H; Panigrahi, H.

doi:10.5958/2321-5836.2020.00027.0

Research Journal of Pharmacology and Pharmacodynamics

2020

DOI: 10.5958/2321-5836.2020.00027.0

|View full text |Cite

Ayurvedic management of kampavata (Parkinson's disease) - A case study report

Srinibash Sahoo¹,

Shashidhar H Doddamani²,

H. Panigrahi³

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Therapeutic effect of Embelin and Levodopa combination in Rotenone induced Parkinson’s disease in mice on Neurobehavioral Changes

Koppal,

H. R,

Sivanesan

et al. 2023

RJPT

View full text Add to dashboard Cite

Objective: The present work evaluated the therapeutic potential of embelin monotherapy, embelin plus levodopa (L-Dopa) combination therapy in rotenone induced Parkinson’s disease (PD) model mice. Scope: Based on several growing evidence, antioxidants can be considered as modifiable factors that eventually decrease the risk of degeneration and progression of PD. Especially anti-oxidants from herbal medicines play vital role against several degenerative diseases. Therefore, we evaluated the neuroprotective effect of embelin and embelin plus L-Dopa therapy in rotenone induced behavioural changes in mice. Methods: Swiss Albino male adult mice were randomly divided into 7 groups. Group-1 (Control) 2mL/kg olive oil by oral route (p.o.), Groups from 2 to 7 were induced with 2.5mg/kg rotenone by intraperitoneal route (i.p.), L-Dopa 7.5mg/kg p.o was administered to Group-3. Group-4 and Group-5 were given 20mg/kg and 40mg/kg embelin p.o. Group 6 and 7 were given embelin p.o. at a dose of 20mg and 40mg/kg respectively along with 7.5mg/kg L-Dopa p.o. Result: Administration of rotenone (2.5mg/kg) for twenty-one days to mice consecutively produced motor incoordination, decreased locomotor activity anxiety like behaviours and bradykinesia. Embelin monotherapy as well as combination therapy of embelin along with L-Dopa significantly decreased the effect of rotenone on behavioural changes and rendered neuroprotection in a dose dependant manner.

show abstract

Therapeutic effect of Embelin and Levodopa combination in Rotenone induced Parkinson’s disease in mice on Neurobehavioral Changes

Koppal,

H. R,

Sivanesan

et al. 2023

RJPT

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Ayurvedic management of kampavata (Parkinson's disease) - A case study report

Cited by 1 publication

References 0 publications

Therapeutic effect of Embelin and Levodopa combination in Rotenone induced Parkinson’s disease in mice on Neurobehavioral Changes

Therapeutic effect of Embelin and Levodopa combination in Rotenone induced Parkinson’s disease in mice on Neurobehavioral Changes

Contact Info

Product

Resources

About